P.P.M. van Lümig

‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the Bio<scp>CAPTURE</scp>network

J. M. P. A. van den Reek, Jeffrey Zweegers, Wietske Kievit et al. · British Journal of Dermatology · 2014 · 97 citations

Medicine, Dermatology, Pharmacotherapy +10

Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis

S.P. Menting, P.P.M. van Lümig, Anna-Christa Q. de Vries et al. · JAMA Dermatology · 2013 · 81 citations · Full text

Life Sciences, Dermatology, Immunology +17

Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-t

Jeffrey Zweegers, J.M.P.A. van den Reek, P.C.M. van de Kerkhof et al. · British Journal of Dermatology · 2016 · 78 citations

Medicine, Pharmacology, Pharmacotherapy +13

An increased risk of non‐melanoma skin cancer during <scp>TNF</scp>‐inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease‐related factors

P.P.M. van Lümig, S.P. Menting, J. M. P. A. van den Reek et al. · Journal of the European Academy of Dermatology and Venereology · 2014 · 67 citations · Full text

Medicine, Clinical Sciences, Dermatology +16

Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry

Jeffrey Zweegers, J.M.M. Groenewoud, J. M. P. A. van den Reek et al. · British Journal of Dermatology · 2016 · 54 citations

Medicine, Dermatology, Pharmacotherapy +11